Updated EAU and AUA/SUO Guidelines for HR-NMIBC

The European Association of Urology (EAU) and the American Urological Association (AUA)/Society of Urologic Oncology (SUO) recently released substantial updates to their clinical guidelines for managing high-risk non-muscle invasive bladder cancer (HR-NMIBC). The revisions include enhanced risk stratification methods, emphasizing precise categorization of tumor aggressiveness to guide optimal therapeutic decisions. Additionally, the guidelines have updated recommendations on diagnostic pathways, surveillance intervals, and appropriate use of imaging technologies such as MRI, reflecting current evidence-based best practices. The guidelines also underscore improved pathology techniques for accurate tumor characterization and management of specific histological subtypes. These collective updates aim to standardize patient care, optimize clinical outcomes, and streamline therapeutic decisions across diverse clinical settings globally, ultimately leading to more personalized and effective patient management.

Citation: EAU, 2025. Available at: https://uroweb.org

Implication: Enhanced guidelines will standardize and elevate NMIBC management worldwide, improving patient outcomes.